Washington – On July 14th, U.S. Sen. Chris Coons (D-Del.), a member of the Senate Competitiveness Caucus, highlighted the critical role of the University of Delaware’s National Institute for Innovation in Manufacturing Biopharmaceuticals, or NIIMBL, in driving research, development, manufacturing, and delivery of therapeutics and biopharmaceuticals for the world.
As part of today’s event, Commerce Secretary Gina Raimondo announced that $153 million in funding is being awarded to NIIMBL in grants to lead a national manufacturing effort to prevent, prepare for and respond to coronavirus outbreaks.
“My hope is that [NIIMBL] will lead not just to innovation on that site in Newark, Delaware, of course, but all over our country, that it will lead to thousands of jobs, not just in Delaware, but all over our country, and that it will deliver solutions for the challenges facing our country,” Sen. Coons said during his speech.
“I’m going to continue to push for more funding, to push for more broad and bipartisan support, to push for more institutes and models that look just like this one,” he continued, “because I am confident that together, we can solve the challenges facing not just our country, but the world.”
NIIMBL, an organization long championed by Sen. Coons, is a public-private partnership designed to accelerate innovation in the U.S. biopharmaceutical industry, producing vaccines, monoclonal antibodies, gene therapies, and other medical products derived from biological sources. NIIMBL is a Manufacturing USA® institute sponsored by the Department of Commerce.